down arrow

Talphera, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US00444T2096
USD
1.26
0.00 (0.00%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

1.231.32

52 Week

0.381.57
Valuation
Technical
Day's Volume

CASH

534.18 k

Shareholding (Mar 2025)

FII

11.87%

Held by 5 FIIs

DII

85.66%

Held by 3 DIIs

Promoter

0.00%

How big is Talphera, Inc.?

22-Jun-2025

As of Jun 18, Talphera, Inc. has a market capitalization of 9.74 million, with net sales of 0.03 million and a net profit of -11.72 million over the latest four quarters. The company's shareholder's funds are 8.00 million, and total assets are 18.24 million.

Market Cap: As of Jun 18, Talphera, Inc. has a market capitalization of 9.74 million, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Talphera, Inc. reported net sales of 0.03 million and a net profit of -11.72 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to 8.00 million, while total assets were reported at 18.24 million.

Read More

What does Talphera, Inc. do?

22-Jun-2025

Talphera, Inc. is a micro-cap specialty pharmaceutical company focused on developing therapies for acute pain. As of March 2025, it reported net sales of $0 million and a net loss of $3 million, with a market cap of $9.74 million.

Overview:<BR>Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain, operating within the Pharmaceuticals & Biotechnology industry and classified as a micro-cap company.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: -3 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 9.74 Million (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.20 <BR>Return on Equity: -243.19% <BR>Price to Book: 1.74<BR><BR>Contact Details:<BR>Address: 351 Galveston Dr, REDWOOD CITY CA: 94063-4736 <BR>Tel: 1 650 2163500 <BR>Fax: 1 650 2166500 <BR>Website: http://www.acelrx.com

Read More

Who are in the management team of Talphera, Inc.?

22-Jun-2025

As of March 2022, the management team of Talphera, Inc. includes Mr. Adrian Adams (Independent Chairman), Mr. Vincent Angotti (CEO), Dr. Pamela Palmer (Co-Founder and CMO), and several independent directors: Dr. Richard Afable, Mr. Mark Edwards, Dr. Stephen Hoffman, Mr. Howard Rosen, and Mr. Mark Wan. This team provides executive leadership and governance for the company.

As of March 2022, the management team of Talphera, Inc. includes the following individuals:<BR><BR>- Mr. Adrian Adams, Independent Chairman of the Board<BR>- Mr. Vincent Angotti, Chief Executive Officer and Director<BR>- Dr. Pamela Palmer, Co-Founder, Director, and Chief Medical Officer<BR>- Dr. Richard Afable, Independent Director<BR>- Mr. Mark Edwards, Independent Director<BR>- Dr. Stephen Hoffman, Independent Director<BR>- Mr. Howard Rosen, Independent Director<BR>- Mr. Mark Wan, Independent Director<BR><BR>This team comprises a mix of executive leadership and independent directors, contributing to the governance and strategic direction of the company.

Read More

Is Talphera, Inc. overvalued or undervalued?

25-Jun-2025

As of November 8, 2023, Talphera, Inc. is considered overvalued due to its negative financial metrics, including a negative P/E ratio, a Price to Book Value of 1.87, a ROCE of -206.75%, and a year-to-date stock return of -16.05%, significantly underperforming the S&P 500.

As of 8 November 2023, Talphera, Inc. has moved from a grade of risky to does not qualify, indicating significant concerns regarding its financial health. The company is currently assessed as overvalued, particularly given its negative P/E ratio due to losses, a Price to Book Value of 1.87, and an alarming ROCE of -206.75%. The EV to EBITDA ratio stands at -0.83, further highlighting the company's struggles in generating earnings relative to its enterprise value.<BR><BR>When compared to peers, Talphera's valuation metrics are concerning. For instance, Tonix Pharmaceuticals has a P/E of -3.669, while Iterum Therapeutics shows a P/E of -2.0489, both indicating worse performance in terms of profitability. Additionally, Talphera's stock has underperformed significantly against the S&P 500, with a year-to-date return of -16.05% compared to the index's 2.44%. This combination of negative financial ratios and poor stock performance suggests that Talphera, Inc. is indeed overvalued in the current market environment.

Read More

Is Talphera, Inc. technically bullish or bearish?

20-Sep-2025

As of September 9, 2025, Talphera, Inc. shows a mildly bullish technical trend with strong short-term momentum, despite mixed signals from moving averages and a one-year underperformance compared to the S&P 500.

As of 9 September 2025, the technical trend for Talphera, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The Bollinger Bands also reflect a mildly bullish stance on the weekly chart and a bullish stance on the monthly chart. However, the daily moving averages are mildly bearish, suggesting some short-term weakness. The KST shows a bullish weekly signal but a bearish monthly signal, and the OBV is bullish on the monthly timeframe.<BR><BR>In terms of performance, Talphera has had a strong one-month return of 115.77%, significantly outperforming the S&P 500's 2.33% return, but it has underperformed over longer periods, including a one-year return of 3.69% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven by the positive signals from the MACD and Bollinger Bands, despite some mixed signals from moving averages and KST.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 17 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.04

stock-summary
Return on Equity

-195.32%

stock-summary
Price to Book

2.54

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-3 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
131.62%
0%
131.62%
6 Months
164.65%
0%
164.65%
1 Year
63.64%
0%
63.64%
2 Years
64.92%
0%
64.92%
3 Years
-43.75%
0%
-43.75%
4 Years
-89.08%
0%
-89.08%
5 Years
-95.59%
0%
-95.59%

Talphera, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Talphera, Inc. technically bullish or bearish?

As of 9 September 2025, the technical trend for Talphera, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, while the monthly MACD is mildly bullish, indicating positive momentum. The Bollinger Bands also reflect a mildly bullish stance on the weekly chart and a bullish stance on the monthly chart. However, the daily moving averages are mildly bearish, suggesting some short-term weakness. The KST shows a bullish weekly signal but a bearish monthly signal, and the OBV is bullish on the monthly timeframe. In terms of performance, Talphera has had a strong one-month return of 115.77%, significantly outperforming the S&P 500's 2.33% return, but it has underperformed over longer periods, including a one-year return of 3.69% compared to the S&P 500's 17.14%. Overall, the current technical stance is mildly bullish, driven by the positive signals from the MACD and Bollinger Bands, despi...

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-63.11%
EBIT Growth (5y)
11.67%
EBIT to Interest (avg)
-17.35
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.20
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
40.66%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.87
EV to EBIT
-0.83
EV to EBITDA
-0.83
EV to Capital Employed
1.72
EV to Sales
11.60
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-206.75%
ROE (Latest)
-243.19%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Mildly Bullish
Mildly Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 4 Schemes (2.47%)

Foreign Institutions

Held by 5 Foreign Institutions (11.87%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -29.63% vs -42.11% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-3.70",
          "val2": "-2.90",
          "chgp": "-27.59%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.50",
          "val2": "-2.70",
          "chgp": "-29.63%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-108,000.00%",
          "chgp": "10,800.00%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -26.21% vs -119.11% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.70",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-15.30",
          "val2": "-16.60",
          "chgp": "7.83%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.40",
          "val2": "0.10",
          "chgp": "300.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "2.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-13.00",
          "val2": "-10.30",
          "chgp": "-26.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "-25,943.20%",
          "chgp": "2,594.32%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQstock-summary
Jun'25
Mar'25
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-3.70
-2.90
-27.59%
Interest
0.00
0.00
Exceptional Items
0.10
0.20
-50.00%
Consolidate Net Profit
-3.50
-2.70
-29.63%
Operating Profit Margin (Excl OI)
0.00%
-108,000.00%
10,800.00%
USD in Million.
stock-summary Compare with Peers
Net Sales

QoQ Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Mar 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -29.63% vs -42.11% in Mar 2025

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.70
-100.00%
Operating Profit (PBDIT) excl Other Income
-15.30
-16.60
7.83%
Interest
0.40
0.10
300.00%
Exceptional Items
2.00
0.00
Consolidate Net Profit
-13.00
-10.30
-26.21%
Operating Profit Margin (Excl OI)
0.00%
-25,943.20%
2,594.32%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2024 is -100.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -26.21% vs -119.11% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Talphera, Inc. stock-summary
stock-summary
Talphera, Inc.
Pharmaceuticals & Biotechnology
AcelRx Pharmaceuticals, Inc is a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidates include DSUVIA (known as DZUVEO in Europe) and Zalviso. Its DSUVIA is indicated for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain. DSUVIA is designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. Its Zalviso is a sufentanil sublingual tablet system intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 microgram (McG), delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system.
Company Coordinates stock-summary
Company Details
351 Galveston Dr , REDWOOD CITY CA : 94063-4736
stock-summary
Tel: 1 650 2163500
stock-summary
http://www.acelrx.com
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."